Anti-L-selectin aptamers: Binding characteristics, pharmacokinetic parameters, and activity against an intravascular target in vivo

Antisense and Nucleic Acid Drug Development

Volumn 10, Issue 2, 2000, Pages 63-75

  Watson, Susan R ^a   Chang, Ying Fon ^a   O'Connell, Dan ^a   Weigand, Laurie ^a   Ringquist, Steven ^a   Parma, David H ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; L SELECTIN; MACROGOL; OLIGONUCLEOTIDE; RNA; SINGLE STRANDED DNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BINDING; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG TARGETING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; RAT; SCID MOUSE;

ANIMALIA;

EID: 0034057416     PISSN: 10872906     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.1.2000.10.63     Document Type: Article

References (22)

1. BRADELY, L.M., WATSON, S.R., and SWAIN, S.L. (1994). Entry of naive CD4 T cells into peripheral lymph nodes requires L-selectin. J. Exp. Med. 180, 2401-2406.
2. DAVIES, B., and MORRIS, T. (1993). Physiological parameters in laboratory animals and humans. Pharm. Res. 10, 1093-1095.
3. EATON, B.E., GOLD, L., and ZICHI, D.A. (1995). Let's get specific: The relationship between specificity and affinity. Chem. Biol. 2, 633-638.
4. FLOEGE, J., OSTENDORF, T., JANSSEN, U., BURG, M., RADEKE, H.H., VARGEESE, C., GILL, S.C., GREEN, L.S., and JANIC, N. (1999). Novel approach to specific growth factor inhibition in vivo. Am. J. Pathol. 154, 169-179.
5. GOLD, L. (1995). Oligonucleotides as research, diagnostic, and therapeutic agents. J. Biol. Chem. 270, 13581-13584.
6. GOLD, L., POLISKY, B., UHLENBECK, O., and YARUS, M. (1995). Diversity of oligonucleotide functions. Annu. Rev. Biochem. 64, 763-797.
7. GREEN, L.S., JELLINEK, D., BELL, C., BEEBE, L.A., FEISTNER, B.D., GILL, S.C., JUCKER, P.M., and JANJIC, N. (1995). Nuclease-resistant nucleic acid ligands to vascular permeability factor/vascular endothelial growth factor. Chem. Biol. 2, 683-695.
8. GREEN, L.S., JELLINEK, D., JENISON, R., OSTMAN, A., HELDIN, C.H., and JANJIC, N. (1996). Inhibitory DNA ligands to platelet-derived growth factor B-chain. Biochemistry 35, 14413-14424.
9. HICKE, B.J., WATSON, S.R., KOENIG, A., LYNOTT, C.K., BARGATZE, R.F., CHANG, Y.F., RINGQUIST, S., MOON-MCDER-MOTT, L., JENNINGS, S., FITZWATER, T., HAN, H.L., VARKI, N., ALBINANA, I., WILLIS, M.C., VARKI, A., and PARMA, D. (1996). DNA aptamers block L-selectin function in vivo. Inhibition of human lymphocyte trafficking in SCID mice. J. Clin. Invest. 98, 2688-2692.
10. JELLINEK, D., GREEN, L.S., BELL, C., LYNOTT, C.K., GILL, N., VARGEESE, C., KIRSCHENHEUTER, G., MCGEE, D.P., ABESINGHE, P., PIEKEN, W.A., and JANJIC, N. (1995). Potent 2′-amino-2′-deoxypyrimidine RNA inhibitors of basic fibroblast growth factor. Biochemistry 34, 11363-11372.
11. JENISON, R.D., JENNINGS, S.D., WALKER, D.W., BARGATZE, R.F., and PARMA, D. (1998). Oligonucleotide inhibitors of P-selectin-dependent neutrophil-platelet adhesion. Antisense Nucleic Acid Drug Dev. 8, 265-279.
12. O'CONNELL, D., KOENIG, A., JENNINGS, S., HICKE, B., HAN, H.L., FITZWATER, T., CHANG, Y.F., VARKI, N., PARMA, D., and VARKI, A. (1996). Calcium-dependent oligonucleotide antagonists specific for L-selectin. Proc. Natl. Acad. Sci. USA 93, 5883-5887.
13. PAGRATIS, N.C., BELL, C., CHANG, Y.-F, JENNINGS, S., FITZWATER, T., JELLINEK, D., and DANG, C. (1997). Potent 2′-amino-, and 2′-fluoro-2′deoxynucleotide RNA inhibitors of keratinocyte growth factor. Nature Biotechnol. 15, 68-73.
14. RINGQUIST, S., and PARMA, D. (1998). Anti-L-selectin oligonucleotide ligands recognize CD62L-positive leukocytes: Binding affinity and specificity of univalent and bivalent ligands. Cytometry 33, 394-405.
15. ROWLAND, M., and TOZER, T.N. (1995). Clinical Pharmacokinetics Concepts and Applications. (Williams & Wilkins, Baltimore).
16. RUCKMAN, J., GREEN, L.S., BEESON, J., WAUGH, S., GILLETTE, W.L., HENNINGER, D.D., CLAESSON-WELSH, L., and JANJIC, N. (1998). 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J. Biol. Chem. 273, 20556-20567.
17. SPERTINI, O., KANSAS, G.S., REIMANN, K.A., MACKAY, C.R., and TEDDER, T.F. (1991). Function and evolutionary conservation of distinct epitopes on the leukocyte adhesion molecule-1 (TQ-1, Leu-8) that regulates leukocyte migration. J. Immunol. 147, 942-949.
18. SPERTINI, O., SCHLEIFFENBAUM, B., WHITE-OWEN, C., RUIZ, P., JR., and TEDDER, T.F. (1992). J. Immunol. Methods 156, 115-123.
19. SPRINGER, T.A. (1994). Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm. Cell 76, 301-314.
20. TUCKER, C.E., CHEN, L.S., JUDKINS, M.B., FARMER, J.A., GILL, S.C., and DROLET, D.W. (1999). Detection and plasma pharmaco-kinetics of an anti-vascular endothelial growth factor oligonucleotide-aptamer (NX1838) in rhesus monkeys. J. Chromatogro B 732, 203-212.
21. TUERK, C., and GOLD, L. (1990). Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249, 505-510.
22. YARUS, M., and BERG, P. (1969). Recognition of tRNA by isoleucyl-tRNA synthetase. Effect of substrates on the dynamics of tRNA-enzyme interaction. J. Mol. Biol. 42, 171-189.